A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.

Highlighting these recently formed companies: Causa Research, Indi Molecular, Nanoly Bioscience, NovoPedics, Stem Cell Theranostics, and STBL Medical Research.

Bacteria continue proving themselves immensely capable of resisting formerly effective antibiotics, and likewise capable of thwarting drugmakers’ efforts to create new types of compounds. The founders of BioVersys AG believe they can identify compounds uniquely able to block certain bacterial resistance factors; they aim to develop such molecules as adjuvants to be given in combination with existing antibiotics, to help restore their potency.

As interest in vulnerable plaque heats up, medical device companies hope to capitalize on their earl y lead. But as vulnerable plaque shifts therapies from structural to biological, that lead many not last long. The second of a two-part series.